Selecting drug regimens in human leukemia.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002463:Cell Membrane Permeability / Q000187:drug effects; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004338:Drug Combinations; D004351:Drug Resistance; D005500:Follow-Up Studies; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D009711:Nucleotides / Q000096:biosynthesis; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D004338:Drug Combinations; D009711:Nucleotides; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate